We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Blood Test Detects Myocardial Infarction

By LabMedica International staff writers
Posted on 22 Mar 2011
A sensitive assay has been used to detect myocardial infarction (MI) within two hours of a patient being admitted to hospital.

An increase in the concentration of troponin in the blood is used to detect whether patients with acute coronary syndrome (ACS) have myocardial infarction and this can be used as a diagnostic marker.

A study performed at the Catharina Hospital, (Eindhoven, The Netherlands), examined the concentration of troponin in 157 patients with suspected non-ST elevated ACS. Blood was drawn on arrival (T0) and 2 (T2), 6 (T6) and 12 (T12) hours later. Levels of cardiac troponin I, creatine kinase–myocardial band fraction (CK-MB) and myoglobin were measured on an immunochemistry analyzer. The assay for troponin was the second-generation TnI-Ultra troponin kit and all tests were analyzed on the manufacturer's Advia Centaur analyzer, (Siemens Healthcare Diagnostics; Erlangen, Germany).

The TnI-Ultra troponin kit is a second-generation, high-sensitivity test with a 10% coefficient of variation (CV) at 0.05 μg/L and a troponin concentration of 0.06 μg/L at the 99th percentile of a reference population. The 99th percentile was established on 221 samples from outpatients with no history of myocardial disease. At T2, a troponin concentration above the MI cutoff is 87% sensitive and 100% specific for MI detection. A difference of more than 30% between the troponin measurements at T0 and T2 in the absence of an absolute troponin increase above the 99th percentile of a reference population was also considered indicative of MI, the sensitivity increases to 100% and specificity decreases to 87%.

The authors concluded that by using a sensitive troponin assay and simple algorithms, the diagnosis of MI can be determined within two hours after arrival at the emergency department, and the measurement of myoglobin and creatine kinase–MB has no added value. The study was published in March 2011 in the American Journal of Clinical Pathology.

Related Links:
Catharina Hospital
Siemens Medical Solutions Diagnostics


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.